Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

EGM Statement

20 Nov 2007 12:08

ReGen Therapeutics PLC20 November 2007 Results of Extraordinary General Meeting ReGen Therapeutics Plc (the "Company") announces that, at the ExtraordinaryGeneral Meeting of the Company held earlier today, Shareholders passed all theresolutions including the resolution relating to the proposed share capitalconsolidation of the Company, as detailed in the circular sent to Shareholdersdated 26 October 2007 (the "Capital Consolidation"). The expected timetable for the Capital Consolidation is as follows: Record Date for Capital Consolidation: 6.00 p.m. on 20 November 2007 Commencement of Dealings in New Ordinary Shares 8.00 a.m. on 21 November 2007 CREST Accounts credited with New Ordinary Shares 21 November 2007 Despatch of certificates for New Ordinary Shares by 27 November 2007 Despatch of cheques for fractional entitlements and certificates for New Ordinary Shares; CREST accounts credited with value of fractional entitlements by 10 December 2007 Application has been made to the London Stock Exchange for the New OrdinaryShares arising on the Capital Consolidation to be admitted to trading on AIM on21 November 2007. Notes: If any of the above times and/or dates change, the revised times and/or dateswill be notified to Shareholders by announcement through a RegulatoryInformation Service. References to time in this announcement and the Notice of Extraordinary GeneralMeeting are to British Time. For further enquiries: Percy Lomax, Chairman and Chief Executive, ReGen Therapeutics Plc Tel: 020 7153 4920 Direct: 020 8504 2156 Mobile: 07932 751541 Roland Cornish, Beaumont Cornish Limited Tel: 020 7628 3396 Nick Bealer, King & Shaxson Capital Limited Tel: 020 7426 5986 Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 Mobile: 07785 297111 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 202112:30 pmRNSAccustem Update
30th Mar 20217:00 amRNSP2 Study in Moderate to Severe Covid-19 Patients
29th Mar 20211:02 pmRNSUpdated: Gabriele Cerrone, Bloomberg Interview
29th Mar 20217:00 amRNSChairman of Tiziana to give interview on Bloomberg
26th Feb 20217:00 amRNSTiziana Interview to Air on Bloomberg TV
16th Feb 20212:37 pmRNSTiziana at BIO CEO & Investor Digital Conference
5th Feb 20217:10 amRNSDirector/PDMR Shareholding
5th Feb 20217:00 amRNSAPPOINTMENT OF DIRECTOR
3rd Feb 20217:00 amRNSCEO exclusive interview to discuss COVID-19 Trial
2nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:36 pmRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20217:00 amRNSPositive Data: Nasal Administration of Foralumab
27th Jan 20217:00 amRNSTiziana files F-3 Statement with U.S. SEC
26th Jan 20217:00 amRNSUpdated corporate presentation
20th Jan 202111:04 amRNSB. Riley Virtual Oncology Investor Conference
20th Jan 20217:00 amRNSAIM Delisting and Admission to the Main Market
13th Jan 20217:00 amRNSAppointment of Chief Medical Officer
11th Jan 20214:46 pmRNSTiziana at J.P. Morgan Healthcare Conference 2021
11th Jan 20212:48 pmRNSTiziana to Present at Biotech Showcase Digital
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:00 amRNSCompletion of Foralumab Clinical Trial in Brazil
18th Dec 202011:13 amRNSPublication of Prospectus
17th Dec 20203:00 pmRNSNotification of Admission to the Main Market
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTiziana Life Sciences to Host Investor Update Call
18th Nov 20202:00 pmRNSDirector/PDMR Shareholding
11th Nov 20207:00 amRNSPhase 1b/2 Clinical Trial - Crohn's Disease
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20209:05 amRNSSecond Price Monitoring Extn
2nd Nov 20209:00 amRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSInitiation of Clinical Trial for COVID-19 Patients
29th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
29th Oct 20207:00 amRNSDemerger Update and Timetable Confirmation
28th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
27th Oct 20204:00 pmRNSDemerger of StemPrintER
26th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
22nd Oct 20204:36 pmRNSIssue of Equity on Exercise of Warrants
21st Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
20th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
2nd Oct 202012:00 pmRNSResult of GM
30th Sep 20207:00 amRNSHalf-year Report
25th Sep 20204:40 pmRNSSecond Price Monitoring Extn
25th Sep 20204:35 pmRNSPrice Monitoring Extension
25th Sep 20207:00 amRNSInterview - Bloomberg International
21st Sep 20202:11 pmRNSPublication of Research Note
21st Sep 20207:00 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.